MESO vs RGEN vs BRKR vs CRL vs TMO

For growth investors, Mesoblast Limited (MESO) is the stronger pick with 191.

4% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 8x trailing P/E (18. 7x forward), making it the more compelling value choice. Analysts rate Mesoblast Limited (MESO) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Thermo Fisher Scientific Inc.

(TMO) is the cheapest at 26. 8x versus Repligen Corporation at 147. 0x. On forward P/E, Charles River Laboratories International, Inc. is actually cheaper at 16. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Mesoblast Limited (MESO) delivered a total return of +6.

0%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: RGEN returned +358. 2% versus MESO's -2. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 1. 07β versus Repligen Corporation's 1. 71β — meaning RGEN is approximately 59% more volatile than TMO relative to the S&P 500. On balance sheet safety, Mesoblast Limited (MESO) carries a lower debt/equity ratio of 21% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Mesoblast Limited (MESO) is pulling ahead at 191.

4% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MESO leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Thermo Fisher Scientific Inc.

(TMO) is the more profitable company, earning 15. 1% net margin versus -593. 9% for Mesoblast Limited — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -363. 1% for MESO. At the gross margin level — before operating expenses — MESO leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Charles River Laboratories International, Inc.

(CRL) trades at 16. 0x forward P/E versus 64. 3x for Repligen Corporation — 48. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 0% to $654. 67.

In this comparison, TMO (0.

4% yield), BRKR (0. 3% yield) pay a dividend. MESO, RGEN, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 07), +222. 6% 10Y return). Mesoblast Limited (MESO) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMO: +222. 6%, MESO: -2. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MESO is a small-cap high-growth stock; RGEN is a small-cap high-growth stock; BRKR is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.